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The efficacies of a series of six muscarinic cholinergic receptor agonists for stimulation of phosphoinositide
breakdown and unidirectional efflux of 45Ca2+ in 1321N1 human astrocytoma cells were compared with the
relative capacity of these agonists for formation of a GTP-sensitive high-affinity binding state in washed
membranes. Carbachol and methacholine were 'full' agonists as regards phosphoinositide breakdown and
Ca2+ mobilization, whereas bethanechol, arecoline and oxotremorine were 'partial' agonists for these two
responses. Pilocarpine was the least efficacious of the six drugs tested. Except for pilocarpine, competition
curves generated with the agonists and [3H]quinuclidinyl benzilate did not follow the Law of Mass Action
for ligand interaction at a single site. Non-linear regression analyses of these data indicated that the data
significantly better fit a two-, rather than a single-, site model with a high- and a low-affinity binding
component. Competition curves generated in the presence of GTP were shifted to the right, and the extent
of receptors in the high-affinity agonist-binding state was decreased. The relative efficacies of the six agonists
for stimulation of phosphoinositide breakdown and Ca2+ mobilization were significantly correlated with
the difference in affinities (KL/KH) between the two affinity states for each agonist. The relative efficacy of
the agonists for stimulation ofCa2+ mobilization also was significantly correlated with the extent of receptors
in the high-affinity state (% H) for each agonist. The results suggest that interaction with an as-yet unidentified
guanine nucleotide regulatory protein is importa-nt in the mechanism whereby muscarinic receptors stimulate
phosphoinositide breakdown in 1321N1 astrocytoma cells.
INTRODUCTION
Cellular responses to muscarinic cholinergic stimuli
have been shown to be associated with both decreases in
intracellular cyclic AMP (Murad et al., 1962; Matsuzawa
& Nirenberg, 1975) and increases in phosphoinositide
turnover and Ca2+ mobilization (Michell, 1975; Michell
et al., 1976; Brown & Brown, 1984; Masters et al., 1984).
Probably the most clearly defined component of
cholinergic action involves the mechanism whereby
receptor stimulation results in an inhibition of adenylate
cyclase. That is, a guanine nucleotide regulatory protein,
Ni, has been shown to couple muscarinic and other
inhibitory receptors to adenylate cyclase (Gilman, 1984).
This guanine nucleotide regulatory protein can be
labelled in the presence of pertussis toxin and [32P]NAD+
(Katada & Ui, 1982; Bokoch et al., 1983), it has been
purified to homogeneity (Bokoch et al., 1984; Codina et
al., 1984), and putative sets of reactions involved in the
interaction of its subunits with other components of the
hormone-responsive adenylate cyclase have been pro-
posed (Gilman, 1984; Katada et al., 1984; Hildebrandt
et al., 1984).
Although much less is known about muscarinic-
receptor-mediated regulation of Ca2+ mobilization,
compelling evidence has been presented implicating the
breakdown of phosphoinositides as a step in receptor-
mediated elevation of cytoplasmic [Ca2+] (Michell et al.,
1981; Berridge, 1984). The mechanisms whereby agonist-
receptor interaction results in stimulation of the
phospholipase C-mediated breakdown of phospho-
inositides remain unknown.
Activation of muscarinic receptors on 1321N1 human
astrocytoma cells attenuates cyclic AMP accumulation
(Meeker& Harden, 1982). This response does not involve
inhibition of adenylate cyclase (Meeker & Harden, 1982;
Hughes et al., 1984), but rather occurs as a consequence
of activation of a Ca2+-calmodulin-dependent phospho-
diesterase (Tanner et al., 1985). The ability of cholinergic
agonists to stimulate phosphodiesterase apparently
results from the stimulatory effect of cholinergic agonists
on phosphoinositide breakdown and Ca2+ mobilization
in this cell line (Masters et al., 1984).
The binding of agonists to muscarinic receptors in
washed membranes from 1321N1 cells is regulated by
guanine nucleotides (Evans et al., 1985). Guanine
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nucleotides also regulate agonist binding to a1-adrenergic
(Boyer et al., 1984), thyroliberin (Hinkle & Kinsella,
1984) and fMet-Leu-Phe (Snyderman, 1984) receptors,
although these receptors, like the cholinergic receptors of
1321N1 cells, act through mechanisms other than
regulation of adenylate cyclase. In addition, a role for
GTP has been proposed in regulation of Ca2+-dependent
effects (Gomperts, 1983; Haslam & Davidson, 1984) and
more recently for receptor-mediated breakdown of
phosphoinositides (Litosch et al., 1985; Cockcroft &
Gomperts, 1985). We show in the current work that the
relative capacity of cholinergic agonists to form a
GTP-sensitive high-affinity binding state is related to
their efficacy for stimulation of phosphoinositide break-
down and 45Ca2+ mobilization. The work implies that a
guanine nucleotide regulatory protein subserves a
function in coupling muscarinic receptors to phospho-
inositide breakdown, and hence to increases in diacyl-
glycerol concentrations and the cytoplasmic
concentration of Ca2 .
MATERIALS AND METHODS
Materials
Drugs, culture medium and supplies were obtained
from sources previously described (Evans et al., 1984,
1985).
Muscarinic cholinergic receptor assay
Competition binding experiments, with [3H]QNB
(20-25 pM) as the radioligand, were performed essentially
as previously described (Evans et al., 1985). Assays were
in 10 ml of 10 mM-Hepes (pH 7.5)/5 mM-MgCl2, and
incubations were carried out at 37 °C for 90 min. Binding
reactions were initiated by the addition of washed mem-
branes and terminated by filtration through Schleicher
and Schuell no. 30 glass-fibre filters. Each filter was
washed with 10 ml of 10 mM-Tris (pH 7.5)/145 mM-
NaCl. Non-specific binding was defined as the amount of
radioligand bound in the presence of 1 ,sM-atropine and
represented < 5% ofthe total radioligand retained by the
filters. Conditions were modified so that < 15% of the
total added radioligand was bound in all experiments. All
assays were performed in triplicate. Agonist-binding
curves were analysed* by computerized non-linear
least-squares-regression analysis as previously described
(Martin et al., 1984). % H is the percentage of receptors
found in a high-affinity binding state for agonists; KH and
KL respectively refer to the affinity of an agonist for the
high- and low-affinity component of binding curves
resolved by computer analysis of curves that better fit a
two-site model.
Phosphoinositide assays
Phosphoinositide hydrolysis was monitored by
measuring the accumulation of the phosphoinositide
metabolite [3H]InsIP, in the presence of LiCl, an
inhibitor of the enzyme that converts InsIP into inositol
(Berridge et al., 1982). Phosphoinositides were radio-
labelled by incubating 1321N1 cell monolayers with
1.0 ml of growth medium containing 1.0,Ci of
myo-[2-3H]inositol (New England Nuclear)/ml for
18-20 h. Just before the assay, the monolayers were
washed with PSS, and assays were initiated by the
addition of warmed PSS containing LiCl (10 mM) and
drugs. To terminate the incubation (10 min), the drug
solution was rapidly removed by aspiration, the mono-
layer was washed with 3 x 1.5 ml of PSS, and 0.5 ml
ofcold methanol was added. Cells were removed from the
dishes by scraping and each dish was rinsed with an
additional 0.5 ml of cold methanol. Then 500 1d of
chloroform and 0.4 ml ofwater were added to the pooled
methanol washes to give a final solution of chloroform/
methanol/water (5:10:4, by vol.), and the samples were
sonicated for 15 s with a Kontes cell disrupter set at the
maximal power setting. An additional 0.5 ml each of
chloroform and water were added, and the resulting
two-phase solution was clarified by centrifugation at
1500g for l5min at 4°C.
InsIP was determined as described previously (Brown
& Brown, 1983). Briefly, 1.6 ml of the upper (aqueous)
phase was transferred to a column containing approx.
175 mg of anion-exchange resin (Bio-Rad AG 1 -X8;
100-200 mesh; formate form). Columns were washed
with 10 ml of water to remove [3H]inositol. Labelled
InsIP was eluted with 8 ml of 200 mM-ammonium
formate/100 mM-formic acid and was counted for
radioactivity in an equal volume of Liquiscint (National
Diagnostics).
Unidirectional 45Ca2+ efflux
Muscarinic-receptor-mediated Ca2+ mobilization was
measured as previously described (Masters et al., 1984).
Cells were equilibrated with 45Ca2+ by incubation with
1.0 ml of growth medium containing 5,Ci of 45CaCl2
(Amersham)/ml for 18-20 h. This period of labelling
allowed the cellular 45Ca2+ to reach a steady state
(achieved by 16 h). To initiate the efflux assay, the growth
medium containing extracellular 45Ca2+ was removed by
aspiration, monolayers were quickly (< 8 s) washed three
times with Hepes (20 mm, pH 7.5)-buffered Eagle's
medium (37 °C) without 45Ca2+, and Hepes-buffered
Eagle's medium (37 'C) containing cholinergic agonists
was added. Incubations were terminated after 1 min by
rapidly washing the monolayers four times with 3 ml of
a solution containing 5 mM-LaCl3, 150 mM-NaCl and
1.5% (w/v) bovine serum albumin. Cells were solubilized
in 1.0 ml of 0.1 M-NaOH, the samples were neutralized
with 1.0 ml of 0.1 M-HCl, and radioactivity was
determined by scintillation counting in 6 ml of Budget-
Solve (RPI). Under the conditions used for measurement
of effects of muscarinic receptor agonists, 45Ca2+ efflux
approximated a first-order exponential with only a single
kinetic component (Masters et al., 1984).
RESULTS
Previous work with chick heart cells (Brown & Brown,
1984), NG108-15 neuroblastoma x glioma cells (Evans et
al., 1984) and other tissues (Jakobs et al., 1979; Olianas
et al., 1983) has indicated that the muscarinic receptor
agonists oxotremorine and carbachol are equally
efficacious as inhibitors of adenylate cyclase activity. In
contrast, carbachol is much more efficacious than
oxotremorine for stimulation of phosphoinositide break-
down and Ca2+ mobilization (Fisher et al., 1983; Masters
et al., 1984; Brown & Brown, 1984). Concentration-effect
curves were generated for six cholinergic agonists to
determine their relative capacities for stimulation of
InsIP formation and 45Ca2+ mobilization in 1321N1 cells
(results not shown). As illustrated in Table 1, a wide range
of relative efficacies was observed when maximally
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Table 1. Relative efficacies of muscarinic-receptor agonists for
stimulation of phosphoinositide breakdown and 45Ca2+
efflux
Phosphoinositide breakdown and 45Ca2+ efflux were
measured in response to a maximally effective concentration
(0.1-1.0 mM) of the indicated agonists. The responses to
agonists in each experiment were compared with that
observed with carbachol (100%). The data are means
+S.E.M. for three experiments.
Phosphoinositide 45Ca2+
Agonist breakdown (%) efflux (%)
Carbachol 100 100
Methacholine 86+ 1 88 + 5
Bethanecol 49+ 2 75 + 2
Arecoline 26+2 64+2
Oxotremorine 11+1 45+1
Pilocarpine 2+1 13+ 5
effective concentrations of these agonists were examined
for their capacity to stimulate phosphoinositide break-
down. Methacholine and carbachol exhibited similar
efficacies, whereas arecoline and bethanecol, like
oxotremorine, were partial agonists compared with
carbachol. Pilocarpine did not measurably increase
Ins 1P accumulation.
The relative efficacy of these six agonists for
stimulation of 45Ca2+ effilux also was measured (Table 1)













the most efficacious agonists, whereas oxotremorine,
bethanecol, arecoline and pilocarpine were partial
agonists for stimulation of Ca2+ effilux.
As we have previously reported (Evans et al., 1984),
carbachol inhibits [3H]QNB binding with high affinity in
1321N1 cell membranes. The competition curve for
carbachol is steepened and markedly shifted to the right
by the addition of 100 juM-GTP (Fig. 1) or by guanosine
5'-[y-thio]triphosphate, GDP or guanosine 5'-[fy-imido]-
triphosphate (Evans et al., 1985). Analogous data were
obtained with the agonist methacholine (Fig. 1): that is,
relatively flat competition curves were obtained in
incubations carried out in the absence of GTP (Fig. 1).
The addition of guanine nucleotide steepened and
markedly shifted the methacholine competition curve to
the right. In contrast with the results obtained with the
full agonists methacholine and carbachol, very little
regulation by guanine nucleotide of the binding of
oxotremorine to 1321N1-cell muscarinic receptors
occurred. No reproducible effect of guanine nucleotides
was observed in competition curves carried out with
pilocarpine (Fig. 1).
A large series of competition curves similar to those
illustrated in Fig. 1 was analysed for six agonists in
accordance with a two-site model as described in the
Materials and methods section. Competition curves for
carbachol, methacholine, arecoline, bethanecol and
oxotremorine in the absence of GTP were significantly
better fitted by a two-site model (Table 2). Pilocarpine
competition curves were not better fitted to a two-site
model. The presence of GTP markedly decreased the
-log {[Agonist] (M)}
Fig. 1. Regulation of agonist interaction with muscarinic receptors by GTP
Washed membranes from 1321N1 cells were incubated in the presence of 20 pM-[3H]QNB,
agonists, and in the absence (0) or presence (M) of 100 ,uM-GTP.
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Table 2. Determination of agonist affinity states for muscarinic cholinergic receptors
Agonist competition curves were generated with 1321Ni cell membranes and [3H]QNB (20-25 pM) in the presence or absence
of GTP (100,UM) or guanosine 5'-[thio]triphosphate (1 uM). Competition curves (see Fig. 1) were analysed by non-linear
least-squares curve fitting of the raw data. The Cheng & Prusoff (1973) approximation was utilized to convert IC50 values into
KH and KL values. To determine if the data were fitted significantly better to a two-site model, the residual sums of squares
of the respective fits were compared by a partial F test. %H and ° L values are means + S.E.M. (n = 3-8). Values for KH and KL
are in SM. The ranges of experimental values are provided in parentheses.
No GTP +GTP
Agonist KH %H KL % L KL/KH KH %H KL % L
Carbachol 0.15 41+2 6.8 59+2 44 0.83 16+5 13 84+5
(0.07-0.29) (3.6-9.9) (0.46-1.8) (8-14)
Methacholine 0.10 43+3 3.6 57+2 37 0.59 18+7 5.6 82+7
(0.05-0.14) (3.0-5.2) (0.28-0.93 (3.3-8.7)
Bethanecol 2.90 58 + 3 106 42+ 3 37 0.53 10+ 7 114 90+ 7
(1.2-4.5) (43-182) (0.33-0.73) (96-133)
Arecoline 0.18 36+2 4.4 64+2 24 0.20 17+ 5 8.6 83 + 5
(0.13-0.24) (1.5-7.1) (0.05-0.35) (8.2-11)
Oxotremorine 0.013 25 + 8 0.22 75 + 8 17 0 0.21 100
(0.009-0.022) (0.19-0.29) (0.15-0.28)















































Fig. 2. Relationship between the ratio KL/KH and efficacy of agonists for stimulation of Ca2+ efflux and phosphoinositide breakdown
The ratio of dissociation constants for low- and high-affinity binding states determined by non-linear-regression analysis of
competition binding curves for the indicated agonists is plotted versus the efficacy of these agonists (relative to carbachol) for
stimulation of Ca2+ efflux (a) or phosphoinositide breakdown (b). Least-squares linear-regression analysis was used to determine
correlation between the ratio KL/KH and biochemical responses. Abbreviations: CAR, carbachol; MET, methacholine; BET,
bethanecol; ARE, arecoline; OXO, oxotremorine; PIL, pilocarpine.
percentage of receptors in the high-affinity form in the
presence ofcarbachol, methacholine, bethanechol, areco-
line or oxotremorine (Table 2); oxotremorine competition
curves in the presence ofGTP were no longer better fitted
by a two-site model (Table 2).
As illustrated in Fig. 2(a), there was excellent
correlation (P < 0.001) between the ratio KL/KH for six
agonists and their capacity to stimulate 45Ca2+ effilux.
Although the correlation was somewhat less striking, the
efficacy for stimulation of phosphoinositide breakdown
was also proportional (P < 0.05) to the value of KL/KH
(Fig. 2b). The correlation between the capacity of these
agonists to form a high-affinity-binding complex (% H)
and their capacity to stimulate Ca2+ mobilization and
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Fig. 3. Relationship between the percentage of receptors in a high-affinity guanine-nucleotide-sensitive
of agonists for stimulation of Ca2+ efflux and phosphoinositide breakdown
binding state and the efficacy
The percentage of receptors in a high-affinity binding state (% H) was determined for a series of agonist competition curves as
described in the Materials and methods section. This value is plotted versus the efficacy of the indicated agonists for stimulation
of Ca2+ efflux (a) or phosphoinositide breakdown (b). Least-squares linear-regression analysis was used to determine correlation
between % H and biochemical responses. For abbreviations, see Fig. 2 legend.
phosphoinositide breakdown was also examined (Fig. 3a).
There was a significant correlation (P < 0.05) between
%H and the capacity of agonists to stimulate 45Ca2+
effilux, but not between H and phosphoinositide break-
down (Fig. 3b).
DISCUSSION
Although there is evidence strongly implicating the
breakdown of phosphoinositides and the generation of
inositol 1,4,5-trisphosphate as crucial steps in receptor-
mediated mobilization ofintracellular Ca2+, the molecular
mechanisms involved in this process are largely unknown
(Michell et al., 1981; Berridge, 1984). This is particularly
true for the steps in the plasma membrane that
immediately result from the initial agonist-receptor
interaction. Thus, whereas the molecular events involved
in agonist-induced coupling of muscarinic receptors to
adenylate cyclase at least tentatively can be assigned
(Gilman, 1984), the events subserving coupling of these
receptors to the phospholipase C involved in phospho-
inositide metabolism are not yet understood.
The current work suggests that an important relation-
ship exists between the efficacies of agonists for
stimulation of phosphoinositide breakdown and Ca2+
mobilization and the formation of a guanine-nucleotide-
sensitive high-affinity-binding complex. The most con-
vincing correlation was observed when the affinity ratios
of the high- and low-affinity forms observed with
individual agonists were compared with their efficacies
for stimulation ofphosphoinositide breakdown and Ca2+
mobilization. In general the correlation was better
between binding parameters and Ca2+ mobilization than
between binding parameters and Ins1P formation. This
may be related to the fact that the immediate product of
phosphoinositide breakdown in these cells is inositol
1,4,5-trisphosphate (Masters et al., 1985b), the second
messenger for Ca2+ mobilization, whereas the inositol
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phosphate (InsIP) that actually was measured in the
experiments is a metabolic product of the second
messenger.
Although the molecular basis for the guanine-
nucleotide-sensitive agonist-binding state of the mus-
carinic receptor in 1321N1 cells is not known, one
interpretation of these data is that a guanine nucleotide
regulatory protein is involved in coupling the agonist-
occupied muscarinic receptor to the enzyme responsible
for phosphoinositide breakdown. Speculation about
these points obviously is influenced by our knowledge of
the role ofa high-affinity complex ofagonist-,/-adrenergic
receptor-N. in the activation of adenylate cyclase (Stadel
et al., 1982), and the fact that the values for KL/KH of
a series of ,-adrenergic-receptor agonists determined in
competition-binding experiments correlated strongly with
the efficacies of the same agonists for stimulation of
adenylate cyclase (Kent et al., 1980).
Computer-based analyses ofcomplex binding curves of
muscarinic receptor agonists were first reported by
Birdsall et al. (1978), although comparisons between
these binding parameters and efficacies of cholinergic
agonists for production of biochemical responses were
not made. Fisher et al. (1983) have published data
obtained with guinea-pig cerebral cortex that may be
analogous to the present results. These workers illustrated
that muscarinic receptor agonists, such as oxotremorine,
that were 'partial' as regards stimulation of phospho-
inositide turnover, inhibited [3H]QNB binding in washed
membrane preparations according to Law-of-Mass-
Action kinetics. In contrast, full agonists, such as
carbachol, inhibited[3H]QNB bindingwith heterogeneous
competition curves that fit a two-site model of high- and
low-affinity forms of the receptor. Although the effect of
guanine nucleotides was not studied by Fisher et al.
(1983), results from the present study suggest that
guanine nucleotides would have markedly shifted the
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little regulation by guanine nucleotides of 'partial'-
agonist binding would have occurred. In other words,
the difference between full and partial agonists would be
that a high-affinity guanine-nucleotide-sensitive state is
formed in the presence of full agonists, but not with
partial agonists.
The ideas put forth in the present paper relating the
capacity ofagonists toinduceaGTP-sensitive high-affinity
binding complex and the efficacy of these agonists for
stimulation of phosphoinositide breakdown are not at
odds with the suggestion that the low agonist affinity
observed in competition curves most closely matched
nituscarinic-receptor-agonist affinity for stimulation of
phosphoinositide turnover (Michell et al., 1976, 1981).
The initial step in agonist action indeed may be its
binding to a low-affinity state of the receptor. We suggest
here that, in addition, the capacity ofthe agonist-occupied
receptor to interact with a guanine nucleotide regulatory
protein (as evidenced by formation of the high-affinity
GTP-sensitive state) is critical for translation of binding
into response.
There are a number of direct observations with other
receptors and tissues that are consistent with the idea that
a guanine nucleotide regulatory protein is involved in
phosphoinositide breakdown and/or Ca2+ mobilization.
Of potential relevance is the report by Gomperts (1983)
suggesting that guanine nucleotides potentiate the
secretory response to Ca2+ in permeabilized mast cells,
and that by Haslam & Davidson (1984) indicating that
guanine nucleotides increase the secretory response of
permeabilized platelets to thrombin. Other circumstantial
evidence for a role of a guanine nucleotide regulatory
protein in phosphoinositide breakdown can be marshalled
from studies ofLimulus. That is, intracellular application
of either active GTP analogues (Fein & Corson, 1981) or
inositol 1,4,5-trisphosphate (Fein et al., 1984) produces
the same physiological response of the photoreceptor cell
as does light. Litosch et al. (1985) have shown that
5-hydroxytryptamine-receptor-mediated breakdown of
phosphoinositides in homogenates and washed mem-
branes of blowfly salivary gland is dependent on the
presence of GTP or a GTP analogue. Guanine
nucleotides also have been shown to stimulate the
breakdown of phosphatidylinositol 4,5-bisphosphate in
human neutrophil plasma membranes (Cockcroft &
Gomperts, 1985).
The insensitivity to inactivation by pertussis toxin of
muscarinic-receptor-mediated attenuation ofcyclicAMP
accumulation (Hughes et al., 1984), muscarinic-receptor-
mediated stimulation of phosphoinositide breakdown
and Ca2+ mobilization (Masters et al., 1985a), and
GTP-sensitive binding ofagonists to muscarinic receptors
(Evans et al., 1985), suggests that Ni is not involved in
cholinergic action in 1321N1 cells. Likewise, muscarinic-
receptor-mediated stimulation of inositol phosphate
formation in chick heart cells is not sensitive to pertussis
toxin (Masters et al., 1985a). The lack ofeffect ofpertussis
toxin on GTP-sensitive agonist binding to az-adrenergic
receptors of rat kidney membranes also suggests that
these receptors, which couple to the phosphoinositide
system (Fain & Garcia-Sainz, 1980), act through a
guanine nucleotide regulatory protein that is not Ni. In
contrast, N1 or an Ni-like protein has been suggested to
fulfil such a role, on the basis of studies with pertussis
toxin in neutrophils (Bokoch & Gilman, 1984; Okajima
et al., 1985) and in mast cells (Nakamura & Ui, 1985).
In summary, hormones that modify cellular function
through Ca2+ mobilization and/or diacylglycerol-
mediated activation of protein kinase C may couple to
their second-messenger system by a mechanism not
dissimilar to that involved in hormone-receptor coupling
to adenylate cyclase. An important goal of future studies
will be to identify the putative guanine nucleotide
regulatory protein involved in receptor-stimulated hydro-
lysis of phosphoinositides.
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